A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

Clinical trial NCT06551324 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06551324
Sponsor: Pfizer
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Start date: 2024-10-21
Primary completion: 2026-12-28
Enrollment: 600

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.